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Abstract
Background Sirtuin 1 (SIRT1) is a NAD+ sensitive deacetylase that has been linked to longevity and has been suggested to
confer beneficial effects that counter aging-associated deterioration. Muscle repair is dependent upon satellite cell function,
which is reported to be reduced with aging; however, it is not known if this is linked to an aging-suppression of SIRT1. This
study tested the hypothesis that Sirtuin 1 (SIRT1) overexpression would increase the extent of muscle repair and muscle func-
tion in older mice.
Methods We examined satellite cell dependent repair in tibialis anterior, gastrocnemius, and soleus muscles of 13 young
wild-type mice (20–30 weeks) and 49 older (80+ weeks) mice that were controls (n = 13), overexpressed SIRT1 in skeletal mus-
cle (n = 14), and had a skeletal muscle SIRT1 knockout (n = 12) or a satellite cell SIRT1 knockout (n = 10). Acute muscle injury
was induced by injection of cardiotoxin (CTX), and phosphate-buffered saline was used as a vector control. Plantarflexor mus-
cle force and fatigue were evaluated before or 21 days after CTX injection. Satellite cell proliferation and mitochondrial func-
tion were also evaluated in undamaged muscles.
Results Maximal muscle force was significantly lower in control muscles of older satellite cell knockout SIRT1 mice compared
to young adult wild-type (YWT) mice (P < 0.001). Mean contraction force at 40 Hz stimulation was significantly greater after
recovery from CTX injury in older mice that overexpressed muscle SIRT1 than age-matched SIRT1 knockout mice (P < 0.05).
SIRT1 muscle knockout models (P < 0.05) had greater levels of p53 (P < 0.05 MKO, P < 0.001 OE) in CTX-damaged tissues
as compared to YWT CTX mice. SIRT1 overexpression with co-expression of p53 was associated with increased fatigue resis-
tance and increased force potentiation during repeated contractions as compared to wild-type or SIRT1 knockout models
(P < 0.001). Muscle structure and mitochondrial function were not different between the groups, but proliferation of satellite
cells was significantly greater in older mice with SIRT1 muscle knockout (P < 0.05), but not older SIRT1 satellite cell knockout
models, in vitro, although this effect was attenuated in vivo after 21 days of recovery.
Conclusions The data suggest skeletal muscle structure, function, and recovery after CTX-induced injury are not significantly
influenced by gain or loss of SIRT1 abundance alone in skeletal muscle; however, muscle function is impaired by ablation of
SIRT1 in satellite cells. SIRT1 appears to interact with p53 to improve muscle fatigue resistance after repair from muscle injury.
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Introduction
Sarcopenia is the age-associated wasting of skeletal muscle
which results in a loss of function.1 Sarcopenia is accompa-
nied by an increased risk for physical disabilities, fall-induced
injuries, hospitalization/institutionalization, and mortality,2
and it is exacerbated by obesity and metabolic disorders.3 Mi-
tochondria regulate muscle metabolism and mitochondrial
dysfunction may play a role in sarcopenia.4 Indeed, altered
size and granularity have been observed in aging mitochon-
dria, 5,6 as well as in the mitochondria of subjects diagnosed
with type 2 diabetes mellitus.7 Concordantly, loss of mito-
chondrial function also occurs with aging and metabolic disor-
ders,8 although some research suggests age-associated
alterations in mitochondrial morphology are independent of
lifespan.9 It is interesting that the highly oxidative type I mus-
cle fibres, which have ~6% mitochondria volume,10 are gener-
ally thought to be more resistant to sarcopenia-related
muscle wasting than type II fibres11 which have ~3% mito-
chondria volume density.10 This might be due in part to a
greater sensitivity of mitochondria in type II fibres to oxida-
tive stress.12 Preserving mitochondrial function is therefore
a potential strategy for reducing sarcopenia in both fibre
types.
Sirtuin 1 (SIRT1) is a class III histone deacetylase13 which is
dependent on NADH to deacetylate its targets, making SIRT1
highly sensitive to changes in metabolism. SIRT1 has been
identified as a link between caloric restriction and longevity,
with the overexpression of SIRT1 linked to increased lifespans
for several organism models.14 Furthermore, SIRT1 has also
been shown to inhibit type I fibre atrophy during intermittent
fasting, by deacetylating and inhibiting the transcription activ-
ity of FoxO1 and FoxO3.15 In addition, activating SIRT1 in
muscle cells prevents the reduction in slower fibre type myo-
sin heavy chain (MHC) gene expression and prevents
myotube wasting after glucose.16,17 Importantly, SIRT1 has
been identified as a regulator of protein peroxisome
proliferator activated receptor gamma coactivator 1α
(PGC1α),18 which is a well-established regulator of mitochon-
drial biogenesis and glycolytic-to-oxidative fibre type
switching in mammalian skeletal muscle.19 PGC-1α activation
(i.e. deacetylation) occurs via AMPK activation of the
deacetylase SIRT1.20 In fact, SIRT1 deacetylation of PGC-1α
increases the expression of key glucose and lipid metabolism
genes.21 However, mitochondrial biogenesis in response to
exercise is not impaired under SIRT1 knock out conditions,
and therefore, SIRT1 deacetylation is thought to be via the
control of acetyltransferase GCN5.22
Satellite cell dysfunction is another potential contributor to
muscle loss in sarcopenia.23 Satellite cells are mononucleated
muscle stem cells that are responsible for the majority of
muscle regeneration after injury.24,25 Both the expression of
SIRT1 and satellite cell populations have been shown to de-
crease with aging,26 inviting the possibility that increasing
SIRT1 expression in older muscle models might act as a coun-
termeasure to preserve muscle regenerative capacity and
therefore improve muscle function after muscle injury in ag-
ing. Consistent with this idea, resistance exercise coupled
with consuming resveratrol, a known activator of SIRT1, in-
creased satellite cell proliferation and improved muscle fibre
size and function in muscles of older humans to a greater ex-
tent than resistance exercise alone.27 Furthermore, resvera-
trol also prevents cell death and increases differentiation of
myotubes,28 whereas SIRT1 silencing evokes greater cell
death and reduced differentiation.28 In addition, SIRT1 was
reported to maintain pools of satellite cells in the state of qui-
escence, and SIRT1 loss of function was reported to invoke
premature differentiation of muscle satellite cells.29 Strength-
ening this argument, mild endurance exercise which in-
creased SIRT1 was shown to rescue an aging-induced
reduction in satellite cell numbers in rats.26,30 However, other
studies have shown differential patterns of SIRT1 expression
according to age and tissue type,31 calling into question
whether aging has universal effects on SIRT1. Thus, there is
a need to further study the role of SIRT1 on mitochondrial
function and satellite cell regulation of muscle repair in the
context of muscle sarcopenia.
The purpose of this study was to investigate the role of
SIRT1 in repairing muscle and restoring skeletal muscle func-
tion after acute muscle damage in older mice. Our hypothesis
was that muscle overexpression of SIRT1 improves mitochon-
drial function and satellite cell activation, which improves
muscle repair and function after acute injury, and in contrast,
loss of SIRT1 in muscle or satellite cells of older mice reduces
muscle repair and function after injury by suppressing satel-
lite cell activation and reducing mitochondrial function. Con-
trary to our expectation, we found that muscle
performance and the recovery of skeletal muscle after injury
are largely unaffected by the abundance of SIRT1 in skeletal
muscle, but ablation of SIRT1 in satellite cells impairs muscle
repair and function. Nevertheless, SIRT1 abundance may
work synergistically with p53 to reduce muscle fatigue after
repair following muscle injury.
Materials and methods
Research design
Two separate experiments were conducted on the five
groups of mice. Three to five mice were examined in each
age group for each experimental comparison. In the first ex-
periment, the plantarflexor muscles (gastrocnemius and so-
leus muscles) received an acute cardiotoxin (CXT)-induced
injury. Plantarflexor force and fatigue were measured before
and then again after 21 days of recovery following CTX injury
to assess the degree that manipulation of SIRT1 protein
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abundance had on muscle function and recovery/repair from
muscle damage. In a separate study, the plantarflexor mus-
cles and the dorsiflexor [tibialis anterior (TA)] muscles from
mice in each of the five groups received a CTX injection to in-
duce acute muscle injury. These muscles were used to assess
the role of SIRT1 on muscle structure solely. As there was the
potential that electrical stimulation to induce evoked contrac-
tions could affect muscle fibre size or structure acutely, we
did not assess muscle function in this second study.
Animal models
Five mouse models were examined. These included (i) young
wild-type (YWT) mice that were 20–30 weeks of age, (ii) older
wild-type mice that were 80–120 weeks of age (WT-80), (iii)
SIRT1 overexpressor older mice that were 80–120 weeks of
age (OE-80), (iv) SIRT1 older adult skeletal-muscle knockout
mice that were 80–120 weeks of age (MKO-80), and (v) SIRT1
satellite cell knockout mice that were 80–120 weeks of age
(SKO-80). As ~50% of the animals died before they were
120 weeks of age, we chose to include older animals that
were 80 weeks of age in our oldest group because this is at
a point where muscle signalling changes and muscle atrophy
and function begins to deteriorate.32,33 While these animals
could not yet be considered to be old, this group had mice that
ranged in age from 80–120 weeks, and the oldest animals in
this group would be considered old. Therefore, we have chosen
to describe this combined group as ‘older’. All wild-type mice
were generated from C57BL/6J background mice purchased
from Jackson Laboratories, USA. MKO-80 and SKO-80
mice were generated using the cre-lox system by crossing
B6;129-Sirt1tm1Ygu/J mice containing loxP sites directing the
removal of exon 4 of SIRT1 with MCK-cre expressing B6.
FVB(129S4)-Tg (Ckmm-cre)5Khn/J and PAX7-cre expressing
Pax7tm1(cre)Mrc/J mice, respectively. Mice that overexpressed
SIRT1 were generated from B6.Cg-Tg (SIRT1)ASrn/J mice
containing a wild-type mouse SIRT1 gene promoted by an
endogenous bacterial artificial chromosome (BAC) transgene.
Cardiotoxin-induced acute muscle injury
Acute muscle injury was induced by injecting the
gastrocnemius, soleus, and TA muscles with 10 μM CTX (Naja
mosambica; Sigma, St. Louis MO, USA)34 in 150 μL of
phosphate-buffered saline (PBS). The contralateral limb was
injected with 150 μL of PBS as a vehicle control. Cage control
recovery occurred for 21 days post-injection. During
recovery, mice were given water containing 0.8 mg/mL of
5-bromo-20-deoxyuridine (BrdU) (MP Biomedicals) to identify
satellite cells that achieved DNA synthesis over the recovery
period as previously used in our lab.24 Post-recovery, the
experimental groups were euthanized by myocardial extraction
under heavy anaesthesia. The muscles were then immediately
collected and frozen in 2-methylbutane (ThermoFisher
Scientific, Pittsburgh PA, USA) chilled by liquid nitrogen. Frozen
tissue sections were mounted on corkboard with Tissue Tek
O.C.T. compound (ThermoFisher Scientific, Pittsburgh PA, USA).
BrdU immunohistochemistry
Frozen tissue sections of control and post-CTX injured
muscles were obtained with a Leica model CM3050S cryostat,
and the tissue was mounted on charged glass slides
(ThermoFisher Scientific, Pittsburgh PA, USA). The frequency
of muscle nuclei that were BrdU positive were measured as
previously described by our lab.24 Briefly, the slides were
fixed at room temperature with 1:1 methanol:acetone
(ThermoFisher Scientific, Pittsburgh PA, USA) and then
permeabilized with PBS in 0.4% Triton X-100. Slides were
then washed with PBS and allowed to incubate in 2 M hydro-
chloric acid (ThermoFisher Scientific, Pittsburgh PA, USA) for
1 h at room temperature, followed by neutralization in
0.1 M Borate Buffer (pH 8.5). The tissue sections were
blocked with 10% normal goat serum (Vector Laboratories,
Burlingame, CA, USA) and incubated overnight in primary
antibodies targeting BrdU (1:100, Developmental Studies
Hybridoma Bank, Iowa City, IA, USA). Secondary antibodies
targeting IgG1 (AlexaFluor-488, Invitrogen-ThermoFisher
Scientific, Carlsbad CA, USA) were used for fluorescent
imaging of BrdU+ nuclei. Images were captured with a Nikon
E800 microscope. BrdU+ cells were quantified using ImageJ
software (National Institutes of Health, Bethesda, Maryland).
BrdU+ labelled nuclei were quantified if they could be clearly
associated with either the periphery or interior of a muscle
fibre. All of the nuclei from six nonoverlapping fields were
quantified with light microscopy at an objective magnification
of 40×. There were two repeats for each biological section
and the data averaged for each section. The BrdU labelling
index was expressed as a percent of the total nuclei and
determined by: (the number of BrdU-positive nuclei
associated with muscle fibres)/(labelled unlabelled nuclei
associated with muscle fibres). Data are presented as
mean ± standard deviation.
Fibre-type immunohistochemistry
Muscle fibre types were identified using antibodies to MHCs
as previously reported by Bloemberg and Quadrilatero,35
with slight modifications as reported by our lab.24 Briefly,
isolated muscles were flash frozen in 2-methylbutane chilled
by liquid nitrogen and mounted on corkboard with Tissue
Tek O.C.T. compound (ThermoFisher Scientific, Pittsburgh
PA, USA). Muscle tissue cross sections were obtained at
20°C with a Leica model CM3050S cryostat. Tissue sections
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were blocked with normal goat serum (Vector Labs, Burlin-
game, CA, USA) and stained with primary antibodies targeting
MHC I (BA-F8S), MHC IIa (SC-71), and MHC IIb (BF-F3), at a
1:100 dilution overnight at 4°C in a humidified chamber.
Primary antibodies were obtained from the Developmental
Studies Hybridoma Bank, Iowa City, IA USA. After washing
with PBS, the slides were incubated in secondary antibodies
at a 1:500 dilution for 2 h at room temperature. Secondary
antibodies targeting IgG2b (AlexaFluor-647), IgGM
(AlexaFluor-546), and IgG1 (AlexaFluor-488) were obtained
from Invitrogen-ThermoFisher Scientific, Carlsbad CA, USA,
and were used for fluorescent imaging. Images were cap-
tured with a Nikon E800 microscope. Fibre cross-sectional
areas (CSA) were determined by planimetry from a minimum
of 500 fibres taken from 8–12 randomly selected fields from
the tissue cross sections. All the fibres encompassed in a field
were traced. Mean fibre area was calculated using ImageJ
software (National Institutes of Health, Bethesda, Maryland).
The cross-sectional images were captured with a Nikon E800
microscope. Whole muscle CSA was determined by tracing
the entire circumference of the muscle section if the section
could be captured as a single image, or otherwise as the sum-
mation of total muscle area traced from a composite picture.
Type I fibre CSA was determined by individually tracing all
fluorescently labelled fibres within a given section, with
(n = 3) muscle sections per group.
Satellite cell isolation
To evaluate the role of SIRT1 on the potential for repair
during aging, mononuclear muscle cells were isolated from
the combined muscle mass of control non-CTX injured
mouse TA and quadriceps muscles from both hindlimbs
using the protocol of Pasut, and colleagues36 with some
modifications. Briefly, muscle samples were cut into small
sections and incubated in 1500 U collagenase type II
(Worthington Biochemical, USA) in Dulbecco’s modified
Eagle’s medium (DMEM) +10% horse serum, followed by
incubation in 300 U collagenase type II with 6 U dispase
(Gibco, Invitrogen, Gaithersburg, MD, USA) in DMEM +10%
horse serum. After trituration, muscle supernatants were
collected and filtered through 40 μm cell strainers
(ThermoFisher Scientific, Pittsburgh PA, USA). Aliquots of
isolated mononuclear cells were then washed in PBS-azide
and blocked in 10% normal goat serum (Vector Labs,
Burlingame, CA, USA). Satellite cells were separated from
the muscle mononuclear cells by labelling the cells with
fluorophore-conjugated primary antibodies as modified
from methods described by Liu et al.37 Briefly, isolated
mononuclear cells were labelled with fluorophore-conjugated
primary antibodies for the following cell surface markers:
CD31 (-APC), Sca-1 (-PacBlue), CD45 (-PE-Cy7), and VCAM-1
(-Biotin) (BioLegend, San Diego, CA, USA). A second incubation
was used to bind Rhodamine-conjugated avidin (Vector Labs,
Burlingame, CA, USA) to the biotin-conjugated antibody.
After washing, the fluorophore-conjugated cells were
resuspended in foetal bovine serum and VCAM+/CD31/
CD45/Sca-1 satellite cells were isolated by a FACSCalibur
flow cytometer equipped with a 15-molecular weight (MW)
488 nm argon laser and 633 nm red diode laser (Becton
and Dickinson). All flow cytometric measurements were
performed in conjunction with the West Virginia University
Flow Cytometry Core Facility.
Protein immunoprecipitation assays
Immunoprecipitation of selected proteins from cell lysates
was conducted as previously reported.38 Briefly, muscle cells
were fractionated by the method described by Rothermel et
al.39 Protein isolates from skeletal muscles were incubated
for 1 h at 4°C with 25 μL of Pierce Protein A/G magnetic
beads (ThermoFisher Scientific, Pittsburgh PA, USA) to reduce
non-specific binding. Clean antigen solutions were then incu-
bated for 2 h at 4°C with an anti-PGC1α primary antibody
(Santa Cruz Biotech. Sant Cruz, CA, USA). Pre-cleaned Protein
A/G beads were next added to the antigen/antibody mixture
and allowed to incubate overnight at 4°C. After the incuba-
tion, the Protein A/G beads were collected with a magnetic
apparatus and the supernatant was discarded. After washing,
the magnetic beads were again collected, and the precipi-
tated proteins were eluted with a 1× NuPAGE LDS sample
buffer (ThermoFisher Scientific, Pittsburgh PA, USA) for
20 min at room temperature. Protein concentrations of sam-
ples were determined by the Lowry method, and the purity of
each fraction was confirmed as reported previously.40 Forty
micrograms of protein were loaded into each well of a 4–12%
gradient polyacrylamide gel (Invitrogen, Carlsbad, CA) and
separated by routine sodium dodecyl sulfate-polyacrylamide
gel electrophoresis for 1 h at 120 V. The proteins were
transferred to a nitrocellulose membrane for 1.5 h at 25 V.
Non-specific protein binding was blocked by incubating the
membranes in 5% nonfat milk in Tris-buffered saline containing
0.05% Tween 20.24,41,42
Mitochondrial isolation
To evaluate the effect of SIRT1 on mitochondria, right and left
non-CTX injured hindlimb plantar flexor muscles were col-
lected from YWT and older SIRT1 variant-expression models,
with both hindlimb flexor groups were pooled into a single
sample. Collected tissues were washed in PBS (pH 7.4).
Subsarcolemmal mitochondria (SSM) and interfibrillar mito-
chondria (IFM) were isolated as previously described.43,44 Mi-
tochondrial pellets were resuspended in KME buffer (100mM
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KCl, 50 mM MOPS, and 0.5 mM EDTA; pH 7.4) for analysis of
mitochondrial enzymatic activity.45,46
Mitochondrial size, internal complexity, and
membrane potential
The size, internal complexity/granulation, and membrane po-
tential of isolated mitochondria were analysed with a
FACSCalibur flow cytometer equipped with a 15-MW
488 nm argon laser and 633 nm red diode laser (Becton
and Dickinson, Franklin Lakes, NJ, USA), as previously de-
scribed.43,45 The ratiometric dye 5,50,6,60-tetrachloro-
1,10,3,30-tetraethylbenzimidazol carbocyanine iodide (JC-1;
Molecular Probes, Carlsbad, CA) was used to selectively
probe and gate for respiring mitochondria47 using 488 nm ex-
citation with 530 and 590 nm bandpass emission filters. A
greater concentration of JC-1 aggregates form as a result of
greater mitochondrial uptake, which increases the orange
fluorescent emission signal, as opposed to the green fluores-
cent monomer of JC-1. The resultant ratio of orange fluores-
cence (polarized mitochondrial membrane) to green
fluorescence (depolarized mitochondrial membrane) was
used to characterize membrane potential for isolated mito-
chondrial subpopulations.
Size and internal complexity/granularity were determined
for mitochondrial populations with forward-scatter (absolute
particle size) and side-scatter (refracted light proportional to
mitochondrial granularity) detectors, respectively. All flow cy-
tometric measurements were performed in conjunction with
the West Virginia University Flow Cytometry Core Facility.
Mitochondrial electron transport chain complex
activities
The activities of mitochondrial complex I, III, and IV and ATP
synthase were determined as previously described.43 Com-
plex I and ATP synthase activities were determined separately
by measuring the oxidation of NADH at 340 nm, while com-
plex III and complex IV activities were determined separately
by measuring the reduction and oxidation of cytochrome c at
550 nm, respectively. Protein content was determined with
the Bradford method, and all complex activities were
expressed in nanomoles of oxygen consumed per minute
per milligram protein.
Muscle force and fatigue
Young wild-type (YWT) and older SIRT1 variant-expression
mouse models underwent measures to determine plantar
flexor force and fatigability to assess the role of SIRT1 on
muscle recovery post-CTX injection. Functional measures
were obtained via indirect electric stimulation of the plantar
flexor muscles through the tibial nerve and measured with
a custom-built dynamometer (Aurora Scientific, Aurora, On-
tario, Canada) as previously described24,38 with the mice
anaesthetised under 2–3% isoflurane.
Electrically evoked contractions (200 μs pulse width) were
measured with the mice on a heated plate to maintain body
temperature under anaesthesia. Hindlimb ankles were posi-
tioned at 90° flexion. The functional assessment began with
a three electrically evoked muscle twitches, followed by a
120 s rest. A second stimulation of 75 Hz was then applied
to induce tetanus followed by a 300 s rest. This was repeated
three times. Finally, a single series of 180 contractions were
performed at 40 Hz (330 ms of activation followed by
670 ms of rest) over a span of 180 s. All stimulations were ap-
plied to the common peroneal nerve with subcutaneous plat-
inum electrons with 200 μs pulse width, via commercially
available stimulator and controlling software provided by Au-
rora Scientific (Aurora, Ontario, Canada). Mice were checked
continually for vitality and responsiveness. After the func-
tional evaluation, the right hindlimb gastrocnemius and so-
leus muscles were each injected with 100 μL of 10 μM CTX
(Naja mosambica) to induce muscle damage34 as described
earlier. An equal volume of PBS was injected into the contra-
lateral leg as a vector control. Muscle recovery/repair oc-
curred for 21 days after CTX injection, and then, the plantar
flexors were examined using the same physiological evalua-
tion. Immediately following the functional measures, the
mice were euthanized by myocardial extraction under heavy
anaesthesia, and the hindlimb muscles were collected for
analysis.
Proliferation analysis
The proliferation potential of isolated populations of satellite
cells was quantified from CTX-injected and control TA mus-
cles using Click-iT EdU Alexa Fluor 488 (Invitrogen-
ThermoFisher Scientific, Carlsbad CA, USA). Briefly, satellite
cells were isolated from TA muscles as described earlier.
The isolated cells were then resuspended in growth medium
DMEM (high glucose, L-glutamine) with 20% foetal bovine se-
rum, 10% horse serum, and 1% antibiotic/antimycotic (Gibco,
Invitrogen, Gaithersburg, MD, USA) and plated overnight on
glass coverslips coated in 0.2% gelatin. Plated satellite cells
were then incubated for 1 h in 10 μM EdU in DMEM. After
incubation, the cells were fixed in 1mL of 3.7% formaldehyde
in PBS for 15 min at room temperature and then washed
twice with 1 mL of 3% bovine serum albumin in PBS. The cells
were then permeabilized in 1 mL of 0.5% Triton X-100 in PBS
for 20 min. After a second wash in PBS +3% bovine serum al-
bumin, cells were treated with 500 μL of reaction buffer,
consisting of copper sulfate, the Alexa Fluor-conjugated
azide, and sodium ascorbate, and then allowed to incubate
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for 30 min at room temperature, protected from light. The
cells then underwent a final wash and were transferred to mi-
croscope slides for analysis with a Nikon E800 microscope.
Coefficients of proliferation were calculated as the number
of illuminated cells counted on nine separate fields divided
by the number of cells plated. Experiments were run in tripli-
cate and are presented as the mean ± standard deviation.
Western blot analysis
Skeletal muscle lysates were analysed with Western immuno-
blots as previously described,24,38,41,42 with slight modifica-
tions. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis was run on 4–12% gradient NuPAGE Bis-Tris
gels (ThermoFisher Scientific, Pittsburgh PA, USA) at 120 V
for 2 h in NuPAGE MES SDS buffer (ThermoFisher Scientific,
Pittsburgh PA, USA). Proteins were transferred to a nitrocellu-
lose membrane for 1 h at 15 V with a Trans-Blot SD semi-dry
transfer cell (Bio-Rad). All proteins were probed at the same
time from the same samples, requiring only GAPDH loading
control. Membranes were then carefully cut to separate the
proteins based on protein MW to allow for the simultaneous
probing of multiple different proteins for each treatment
group. The MW for the proteins were: FoxO3a (80kDA), p53
(53kDA), and GAPDH (35.8kDA). After blocking with TBST
+5% nonfat dry milk, membranes were incubated overnight
at 4°C in 1:1000 dilutions of primary antibodies for SIRT1
(Millipore), PGC1α (Santa Cruz), GAPDH (Cell Signaling, Dan-
vers, MA, USA), p53 (Cell Signaling, Danvers, MA, USA),
Acetyl-Lysine (Cell Signaling, Danvers, MA, USA), and FOXO3a
(Cell Signaling, Danvers, MA, USA). Membranes were then
incubated in linked anti-mouse and anti-rabbit secondary
antibodies at 1:5000 dilutions (Cell Signaling, Danvers,
MA, USA). Horseradish peroxidase (HRP) signals were
developed with an enhanced chemiluminescent substrate
(ThermoFisher Scientific, Pittsburgh PA, USA) with a G:Box
Bioimaging System (Syngene, Fredrick, MD, USA). Band
intensity was normalized to GAPDH.
Verification of antibody specificity
The antibodies which were used in our experiments were val-
idated prior to utilization. We obtained antibodies that were
supplied from vendors which were able to provide validation,
maintenance testing, and production validation to ensure
that lots of the antibodies remained constant over the study
duration. In addition, validation of the antibodies included
testing on appropriate positive protein controls or mouse
models (deficient in gene/protein) by immunoblot and immu-
nostaining. Western blots were conducted to validate band
sizes, and immunohistochemistry on each antibody to check
for non-specific staining in tissue sections. Several different
antibodies to the same protein were used to confirm staining
patterns and/or location of the protein band on a western
blot. Negative controls were conducted without the primary
antibody or without the secondary antibody to confirm that
there was no inappropriate cross-labelling by the antibodies.
Statistical analysis
Quantitative analysis was performed on experiments per-
formed at least in triplicate. Statistically significant differ-
ences between groups were determined using GraphPad
Prism 6 software (La Jolla, CA, USA) performing a two-way
analysis of variance (ANOVA) (age group × condition) with
corrections made for multiple comparisons against a baseline
control group by the Dunnett’s test. Fatigue analysis was per-
formed using two-way repeated ANOVA with corrections for
multiple comparisons against the baseline control. Statistical
differences between right and left hindlimb pretreatment
groups for each genotype were compared using paired t-tests
for muscle force, indicating the difference between hindlimbs
was not significant from zero. Multiple unpaired t-tests for
contractile force as a function of the number of muscle con-
tractions was also performed between the left and right
hindlimb pretreatment groups for each genotype, also indi-
cating no significant difference between hindlimb function
within the individual models. As such, data for the left
hindlimb pretreatment groups were expressed as baseline
data for each model. Unpaired t-tests were also used, when
appropriate, to determine statistical significance between
two groups, such as treatment and control groups within
each genotype, with significant differences noted when pres-
ent. Effect sizes were reported using the Cohen’s d statistic
and were calculated as the difference in means over the
pooled standard deviation. The results were expressed as
mean ± standard deviation (SD) (P < 0.05).
Results
Animal model characteristics
Mouse models were categorized into five groups, based on
age and SIRT1 expression. Young wild-type (YWT) mice were
20–30 weeks of age, while older mice were 80–120 weeks
of age. The older mice included wild-type mice (WT-80),
SIRT1 overexpressor mice (OE-80), SIRT1 adult skeletal-mus-
cle knockout mice (MKO-80), and SIRT1 satellite cell knockout
mice (SKO-80). Each group included both male and female
mice. Although the older mouse groups showed no significant
differences in body weight between males and females, YWT
females were significantly smaller than corresponding YWT
males (P ≤ 0.05) (Table 1).
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SIRT1 protein abundance in the mouse models
To characterize differences in SIRT1 protein abundance be-
tween animal groups, the hindlimb muscles were collected
from young wild-type (YWT, n = 3) and older (80+ weeks)
wild-type (WT-80, n = 3), SIRT1 overexpressor (OE-80,
n = 3), SIRT1 skeletal muscle knockout (MKO-80, n = 3), and
SIRT1 satellite cell knockout (SKO-80, n = 3) mice, 21 days af-
ter PBS or CTX injection. The mice were examined prior to
and 2 h after exercise (-ex) because exercise is a known in-
ducer of SIRT1.48 As expected, SIRT1 was greater in the OE
muscles and lowest in the muscles from SKO and MKO mice
(Figure 1B). These data indicate that SIRT1 protein levels
were as anticipated based on the crosses of the respective
animal models. SIRT1 was not absent in SKO-80mice muscles,
although the SIRT1 protein abundance was significantly lower
in PBS-injected, but not CTX-injected hindlimb muscles from
SKO-80 relative to YWT mice. Interestingly, ANOVA analyses
showed significant differences between the OE-80 PBS and
SKO-80 PBS groups as compared to wild-type controls, but
not the MKO-80 PBS groups. However, the OE-80, SKO-80,
and MKO-80 muscle SIRT1 abundances were significantly dif-
ferent from the wild-type controls when compared with indi-
vidual t-tests (P < 0.05, data not shown). Only the muscles
from SKO-80 mice showed a significant increase in SIRT1
abundance in CTX-injected muscles relative to their own
PBS group (P < 0.05).
We next measured FoxO3a and p53 protein abundance be-
cause they are downstream targets of SIRT1 (Figure 1C). Pro-
tein abundance was not markedly different for FoxO3a
among the groups. Abundance of p53 followed a similar dis-
tribution to the SIRT1 protein expression, although a signifi-
cant difference in p53 protein abundance was not detected
between the OE-80 groups and the YWT PBS control (Fig-
ure 1D). Interestingly, while a significant increase in p53 pro-
tein abundance was not detected between injury-recovered
muscles and muscles treated with the saline control for either
the OE-80 or MKO-80 groups, the relative abundance of p53
for those groups was significantly greater than the p53 abun-
dance detected in muscles from the YWT CTX-injected mice
(comparison denoted by #). Even though the muscle protein
abundance of p53 in the YWT CTX mice differed significantly
from the protein abundance levels in muscles from the OE-
80 CTX and the MKO-80 CTX groups, p53 protein abundance
in muscles from YWT CTX-injected mice did not differ signifi-
cantly from the levels found in muscles from the WT-80 CTX
and the SKO-80 CTX groups (Figure 2C–2H).
We also evaluated the acetylation status of PGC1α, an-
other downstream target of SIRT1 to assess SIRT1 activity
(Figure 1E). Although we expected to see decreased acetyla-
tion of PGC1α in muscles from the SIRT1 overexpressor
mouse model and increased acetylation in the muscles from
SIRT1 knockout mice, qualitative analysis of immunoblots
showed no apparent change in acetylation state, regardless




We tested whether SIRT1 protein abundance had a role in
regulating skeletal muscle function in muscles of older mice
after acute injury induced by CTX. Before treatment, average,
evoked maximal plantar flexion contractile force at 75 Hz
stimulation was significantly lower in the older SKO-80 mice
as compared to YWT PRE, indicating a lower basal contraction
force in older mice deficit of SIRT1 in satellite cell (Figure 2A).
Next, contractile force was assessed in each group following a
21-day recovery from acute injury by CTX or treatment with
PBS to determine if SIRT1 abundance in skeletal muscle had
an effect on the recovery of contractile function. Mean max-
imal contractile force in YWT mice generated at a stimulation
frequency of 75 Hz had recovered to control levels by 21 days
after CTX treatment. The maximal contractile force was signif-
icantly lower in the PBS-injected, vector control hindlimb for
WT-80 compared to the WT-80 PRE baseline, suggesting that
the older muscles in the WT-80 animals may have been sus-
ceptible to injection injury (Figure 2A). As expected, aging
per se resulted in a lower plantar flexion maximal force pro-
duction in wild-type mice, as seen by the lower force
Table 1 Characteristics of study animals
YWT OWT OE MKO SKO
Age (weeks) 24.8 ± 0.7 83.7 ± 0.5 86.9 ± 1.5 90.1 ± 2.9 84.2 ± 4.2
Mass (g)—total 28.4 ± 1.4 35.8 ± 2.1 31.7 ± 0.8 34.9 ± 1.5 31.2 ± 1.7
Mass (g)—males 32.1 ± 1.1* 37.3 ± 2.6 32.7 ± 0.7 34.9 ± 2.0 34.5 ± 2.1
Mass (g)—female 24.0 ± 0.9* 33.5 ± 3.6 29.6 ± 1.7 34.8 ± 2.5 31.4 ± 2.1
Male (%) 53.9 61.6 66.7 58.3 30
Female (%) 46.2 38.5 33.3 41.7 70
n 13 13 14 12 10
Mass of each group was recorded immediately prior to euthanasia. Experimental groups consisted of randomly distributed males and fe-
males. Young wild-type (YWT) males differed significantly in body mass only from YWT females (*P < 0.05). Data are expressed as
means ± SD.
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Figure 1 Protein expression in young wild-type and older variant SIRT1 expressing mice. (A) SIRT1 protein expression collected from 12-week-old wild-
type (WT), overexpressor (OE), satellite cell knockout (SKO), and skeletal muscle knockout (MKO) mice prior to and 2 h after exercise (-ex). (B) Den-
sitometric and immunoblot analysis of SIRT1 protein expression measured in young wild-type (YWT, n = 3) and older (80+ weeks) wild-type (WT-80,
n = 3), SIRT1 overexpressor (OE-80, n = 3), SIRT1 skeletal muscle knockout (MKO-80, n = 3), and SIRT1 satellite cell knockout (SKO-80, n = 3) mice
hindlimbs 21 days after phosphate-buffered saline (PBS) or cardiotoxin (CTX) injection. Basal SKO-80 SIRT1 expression was significantly reduced relative
to YWT mice (*P< 0.05), while OE-80 PBS SIRT1 expression was significantly increased (***P< 0.001) relative to YWT PBS. Only SKO-80mice showed a
significant increase in SIRT1 abundance for CTX injected muscles relative to their own PBS injected hindlimbs (†P < 0.05). (C) Representative immu-
noblots of SIRT1 downstream targets FoxO3a and p53 and loading control GAPDH for SIRT1 variant expressers after PBS/CTX injection and recovery.
Densitometric analysis of the immunoblots revealed no significant differences in protein expression. (D) Densitometric analysis of the immunoblots
revealed significant differences in the abundance of p53 protein for OE-80 CTX (###P < 0.001) and MKO-80 CTX (#P < 0.05) groups relative to YWT
CTX mice. (E) Representative immunoprecipitation immunoblots for SIRT1 downstream target PGC1α and its acetylation state. (F) Densitometric anal-
ysis of relative PGC1α acetylation. No significant difference was discovered between groups versus the YWT control when using one-way analysis of
variance with corrections for multiple comparisons.
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production in the muscles of the WT-80 PBS group relative to
the WT-80 PRE group.
We next compared the percent recovery of contractile
force in hindlimb muscles 21 days post-recovery from CTX in-
jection (Figure 2B). The maximal post PBS-injection or CTX-
injection plantar flexion force was normalized to the respec-
tive pretreatment force output for each animal. The aged
mice were expected to show decreased force recovery in
PBS control hindlimbs relative to the young wild-type mice.
However, despite the WT-80 having a force recovery under
one-fold, no older group showed significantly altered, basal
force recovery in control PBS injected hindlimbs relative to
the YWT PBS group. This suggests that aging did not impair
recovery after injury. Contrary to our original expectations,
Figure 2 The effects of SIRT1 expression on hindlimb skeletal muscle function in young wild-type and older mice. Young wild-type (YWT, 20–30 weeks,
n = 8) and older (80+ weeks) wild-type (WT-80, n = 8), SIRT1 overexpressor (OE-80, n = 9), SIRT1 skeletal muscle knockout (MKO-80, n = 7), and SIRT1
satellite cell knockout (SKO-80, n = 4) mice were anaesthetised with 2–3% isoflurane and electrically stimulated once at 75 Hz (A, B) and 180 times at
40 Hz (C-H) to produce muscle contractions (pretreatment, PRE) prior to injection with snake cardiotoxin (CTX) and vehicle control (PBS). Twenty-one
days post-injection, muscle force was re-examined. Data are presented as the mean force at 75 Hz ± SD (***P< 0.01; †P< 0.05) (* denotes a significant
difference from the YWT control and † denotes a significant difference between a genotype’s control and treatment). (B) Force recoverywasmeasured by
normalizing PBS/CTX data to the same limb pretreatment. Data presented as fold change ± SD. (C) Comparison of all and individual (C–H) fatigue profiles
for experimental groups normalized to earliest maximum force. Data are presented as fold change (†P < 0.05, ††P < 0.01, †††P < 0.01,
††††P < 0.001).
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Figure 3 The effects of SIRT1 expression on hindlimb skeletal muscle structure in young wild-type and older mice (A–E). Gastrocnemius and soleus
muscles for YWT (A), WT-80 (B), OE-80 (C), MKO-80 (D), and SKO-80 (E) were dissected after physiological evaluation and flash frozen in methyl-butane
chilled by liquid nitrogen. Cross sections were cut at 16 μm, stained for MHC I (green) or MHC IIa/b and dystrophin (red), and then mounted with DAPI
hardset (blue). Total cross-sectional area (CSA) of gastrocnemius cross sections (F), soleus cross sections (G), and type I fibre cross sections (H) were
calculated by fibre tracing with the ImageJ software package on images captured at 4x resolution. Data are presented as mean ± SD compared to YWT
PBS, (n = 3). [F*] denotes that a significant difference was observed for the global one-way analysis of variance tests, but not for specific comparisons.
(I) The gastrocnemius type I percentage was calculated by dividing the summed type I fibre CSA for each section by the total CSA of the respective
gastrocnemius (n = 3). Scale bar = 100 μm.
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only the youngest group of mice (YWT) showed decreased re-
covery in maximal hindlimb force from muscles that had been
acutely injured by CTX as compared to PBS treated muscles.
Although the overall plantar flexion force output for SKO-80
hindlimb muscles was significantly lower than YWT mice,
the SKO-80 mice appeared to recover to pretreatment levels
after 21 days of recovery. The relative force produced 21 days
after CTX-induced injury was not diminished in the older SKO-
80 animals as compared to young animals although the abso-
lute levels of force was also depressed in the SKO-80 animals
as compared to other groups.
Muscle fatigue
Muscle fatigability was examined in hindlimb plantar flexor
muscles from young and older mice by inducing a series of
180 electrically evoke contractions at 40 Hz over a period of
3 min. While the mean force output over time shows the
amount of fatigue occurring in a contracting muscle group,
it does not necessarily mimic resistance to fatigue for those
muscles. Therefore, we examined fatigue resistance by
looking at the depletion of muscle contractile force as a func-
tion of consecutive electrically evoked contractions by nor-
malizing the force of each 40 Hz contraction to the force of
Figure 4 The effects of SIRT1 expression on cell replication in older murine skeletal muscle after recovery from injury. (A–D) Tibialis anterior (TA) cross
sections were taken for WT-80 (A), OE-80 (B), MKO-80 (C), and SKO-80 (D) mice 21 days after CTX injury at 4x resolution. Sections were stained against
BrdU (green, indicated by white arrows) and dystrophin (red). (E) Total CSAs of TA cross sections were calculated and presented as mean CSA (μm2) ± SD
(n = 3). (F) BrdU positive nuclei (A–D) were quantified and normalized to their respective TA CSA. Data are presented as mean ± SD (n = 3); (*P< 0.05).
Scale bar = 100 μm. CSA, cross-sectional area
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the initial 40 Hz contraction (Figure 2C–2H). The baseline fati-
gability of the young pretreatment wild-type mice (YWT PRE)
mice did not differ significantly from the fatigability of the
WT-80 PRE, OE-80 PRE, MKO-80 PRE, or SKO-80 PRE groups
(Figure 2D and 2H). Neither acute muscle injury from CTX
nor injection with the PBS vector control had significant ef-
fects on muscle fatigability in YWT, WT-80, or SKO-80 mice
post-recovery (Figure 2D, 2E, and 2H). Surprisingly, muscles
that underwent repair after CTX injury had greater fatigue re-
sistance in both the aged SIRT1 overexpression and skeletal
muscle knockout models of SIRT1 (Figure 2F and 2G). The
OE-80 CTX group showed the greatest magnitude and most
consistent attenuation of fatigue following recovery from
acute muscle injury, and the OE-80 CTX was also the only
group to show signs of post-activation potentiation, so that
muscle contractile force increases with time rather than
diminishing. Although the effect was smaller for the MKO-
80 CTX group compared to the OE-80 CTX mice, protection
from fatigue was present only in muscles that had recovered
from acute CTX injury (Figure 2E–2G), which would have re-
quired activation of satellite cells to induce repair. Interest-
ingly, when compared to the fatigability of YWT CTX mice,
the OE-80 CTX and MKO-80 CTX groups still showed signifi-
cant protective fatigue resistance, albeit to a lesser degree,
and were the only groups to do so. Furthermore, the fatigue
resistance seen in the OE-80 CTX and MKO-80 CTX models co-
incides with the increased abundance of p53 after repair from
CTX as seen in Figure 1C.
Fibre cross-sectional area
Given the greater susceptibility of type II fibres to aging-in-
duced atrophy49 and the general resistance of type I fibres
to sarcopenic changes,50 we decided to investigate the effect
of SIRT1 expression on these two primary muscle fibre types
in the gastrocnemius muscle of older mice. Although the ex-
act fibre type distribution of the mouse gastrocnemius can
vary between strains, the gastrocnemius muscle typically con-
tains a mixture of types I and II muscle fibres although it is
predominantly composed of type II fibres.51 To determine
the effects of SIRT1 expression on gastrocnemius muscle
structure after acute injury, we used immunofluorescence
techniques to determine the CSA of whole muscles, and types
I and II fibres from PBS-injected and CTX-injected gastrocne-
mius muscles of the YWT and older groups (Figure 3F–3H).
As expected, the CSA for the gastrocnemius muscle was
lower in older mice 21 days after PBS-injection or CTX-injec-
tion CSA relative to muscles in YWT mice 21 days after PBS
(Figure 3F). However, we did not find a significant difference
between any older group and the YWT control. Given that the
Cohen’s d test shows effect sizes greater than 2 standard de-
viations for two groups (WT-80 PBS and WT-80 CTX), it is
likely that the absence of significance may have been due
to a low sample size.
Similarly, the CSA in the soleus muscle (Figure 3G) had a
significant F statistical main effect from one-way ANOVA with
corrections for multiple comparisons; however, no significant
differences were found between the YWT PBS control group
and other groups. Groups of mice showing a large effect size
(>1 standard deviation) were YWT CTX, WT-80 PBS, OE-80
CTX, and SKO-80 CTX groups. Next, we calculated mean type
I fibre CSA from each gastrocnemius section (Figure 3A–3E),
from which we calculated the percent type I CSA standard-
ized to the total CSA of the gastrocnemius muscle (Figure 3H).
Despite the apparent difference of the percent of type I fi-
bres, this did not reach a statistically significant difference
when represented as a percentage of the entire gastrocne-
mius muscle CSA or the specific comparisons of the treat-
ment groups to the YWT PBS control.
Regenerative capacity
Loss of function in aging skeletal muscle is characterized by
reduced capacity for muscle satellite cells to regenerate dam-
aged tissue.52 Previously, our lab has used 5-bromo-20-
deoxyuridine (BrdU) administered in water supplied ad
libitum to gauge satellite cell proliferation to an experimental
intervention.24 Therefore, to examine satellite cell division in
response to skeletal muscle regeneration, we injected the TA
muscles of older WT, OE, MKO, and SKO mice with CTX or PBS
as a control and supplied the recovering mice with 0.8mg/mL
of BrdU for 21 days post-injury. After recovery, the mice were
sacrificed, and BrdU expression was identified in the TA or
gastrocnemius muscles by immunohistochemically. The num-
ber of BrdU+ nuclei in CTX-recovery hindlimb muscles were
then counted (Figure 4A–4D) and normalized to the CSA of
their respective muscles. In contrast to the plantar flexor
muscle group, the TAs showed no significant difference be-
tween PBS and CTX-recovery groups for mean muscle CSA
or effect size (Figure 4E). No significant difference was seen
between the MKO-80 and WT-80 groups, while a significantly
lower number of BrdU+ nuclei/μm2 was found for the OE-80
and the SKO-80 CTX-recovery groups (Figure 4F). Neverthe-
less, all animal groups showed effect sizes larger than 1 stan-
dard deviation (P ≤ 0.05).
Next, to determine the regenerative capacity of satellite
cells from the older SIRT1 expression variable mouse models,
we isolated satellite cells by FACS and used them in prolifer-
ation analysis. Isolated satellite cells were diluted so that
10000 cells could be plated in triplicate onto a gelatin-coated
coverslip in a 24 well plate. Cells were allowed to recover
overnight before treatment with 5-ethynyl-20-deoxyuridine
(EdU) prior to fixation and permeabilization. Similar to BrdU,
EdU is incorporated into DNA from proliferating cells. There-
after, images from nine fields from each coverslip were
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captured and the total number of EdU+ cells were counted
(Figure 5A–5D). The proliferation factor was calculated and
expressed as the number of EdU+ cells in nine image fields
over the number of cells initially plated. Satellite cells that
were isolated from muscles of MKO-80 mice showed a signif-
icant increase in proliferation relative to WT-80 mice, with an
effect size greater than 3 standard deviations (Figure 5E).
Mitochondrial structure and function
There is likely a link between mitochondrial dysfunction and
aging53 including sarcopenia.4 As SIRT1 is a known regulator
of PGC1α which in turn regulates mitochondria biogenesis,
we next decided to investigate the effects that SIRT1 expres-
sion levels had on mitochondrial activity in the skeletal
Figure 5 The effects of SIRT1 expression on satellite cell proliferation in older murine skeletal muscle. (A–D) EdU+ cells were identified from FACS-iso-
lated satellite cell populations from TA muscles of WT-80 (A), OE-80 (B), MKO-80 (C), and SKO-80 (D) mice. (E) The proliferation factor was determined
by the total of EdU+ cells counted from nine fields, normalized to the total number of cells in the plate. Experiments were repeated in triplicate, and
data are presented as mean ± SD (n = 3); (*P < 0.05).
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Figure 6 Characteristics of mitochondria in young wild-type and older SIRT1-expression models of murine skeletal muscle. Plantar flexor muscle groups
(gastrocnemius, soleus, and plantaris) were obtained from YWT and older SIRT1-expressor mice prior to isolation of interfibrillar mitochondria (IFM)
and subsarcolemmal mitochondria (SSM) subpopulations. Significant differences were found in the sizes of older mitochondria relative to YWT mito-
chondria for both SSM (A) and IFM (D). No significant differences were found for specific comparisons of internal complexity in SSM (B) or in IFM (E).
OE-80 showed a significantly lower mitochondrial membrane potential (ΔΨm) than YWT mice mitochondria as reflected in the lower ratio of orange/
green mitochondria relative to YWT in SSM (C) and IFM (D) [F*]. MKO-80 mice and OE-80 mice show the potential for having inversely affected ΔΨm
(F). The shift from green to orange occurs as the JC-1 dye forms aggregates upon membrane polarization causing shifts in emitted light from 530
(green) to 590 nm (orange). Addition of 200 μM dinitrophenol, which collapses the ΔΨmwas used as an assay control. Data are expressed as the mean
orange fluorescence divided by the mean green fluorescence of 20000 mitochondrial events per individual mitochondrial sample. The activity for mi-
tochondrial electron transport chain complexes was calculated for SSM (G–J) and IFM (K–N). OWT-80 showed increased complex III activity in SSM (H),
while OE-80mice showed decreased ATP synthase activity (J). Complex IV activity is depressed in older WT and OE models in SSM, but not SIRT1 knock-
out models (I). Data are presented as mean ± SD (n = 5). (*P< 0.05, **P< 0.01, ***P < 0.001). [F*] denotes that a significant difference was observed
for the global one-way analysis of variance tests, but not for specific comparisons.
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muscle of older mice. To determine changes in mitochondrial
size and complexity/granularity, freshly isolated IFM and SSM
subpopulations were analysed in control mice by forward-
scattering and side-scattering light, respectively.44,54 Mito-
chondria were isolated from the same mice that were used
for satellite cell isolation experiments, and therefore, it was
not possible to evaluate mitochondria after CTX experiments
in these mice. Older mice had greater mitochondrial size for
both SSM and IFM relative to YWT control mice for both
SIRT-1 overexpressor and knockout groups (Figure 6A and
6D). No significant difference was found for the internal com-
plexities of IFM or SSM; however, a significant F ratio was
found for the SSM internal complexity, despite having no sig-
nificant differences among the groups relative to the YWT
control (Figure 6B and 6E).
Changes in mitochondrial membrane potential (ΔΨm) typ-
ically occur in tangent with diseases like diabetes45,54 and also
in aging.55 Isolated mitochondria were incubated with
5,50,6,60-etrachloro-1,10,3,30-tetraethylbenzimidazol
carbocyanine iodide (JC-1). A shift from JC-1 green to red
fluorescence indicated an increase in the ΔΨm. Previous
studies have shown mitochondria from diabetic animals or
humans had a greater orange/green ratio as compared to
control mitochondria.45,54 A significantly lower ΔΨm was
found in SSM populations for OE-80 mice relative to YWT
control mice as reflected by a lower orange/green fluorescent
ratio (Figure 6C). A similar decrease in ΔΨm was seen for the
IFM mitochondria in OE-80 mice, although statistical signifi-
cance was not achieved (Figure 6F). While significant differ-
ences for ΔΨm were not found between groups, a one-way
ANOVA with corrections for multiple variances with the
Dunnett’s test (P = 0.05), the global analyses revealed a sta-
tistical difference between the group means. Given the large
effect sizes for some of the groups (>1 SD), it is possible that
the marginally non-significant pairwise contrasts in (Figure 6F)
may have produced a significant difference if there the exper-
imental sample size had been larger.
Mitochondrial complex activity and muscle repair
To further examine the effects of variant SIRT1 expression
coupled with aging on mitochondria, we next assessed the
relative activity of the mitochondrial electron transport
chain complexes in control muscles. These same mice were
used for satellite cell isolation experiments, and therefore, it
was not possible to evaluate mitochondria following CTX in-
jury in these mice. Significant differences were found for ac-
tivities of the SSM complexes, specifically a greater complex
III activity for WT-80 mice (Figure 6H) and a reduced ATP
synthase activity for OE-80 mice (Figure 6J). No significant
change was seen for SSM complex I activity (Figure 6G) or
SSM complex IV activity (Figure 6I), although the one-way
ANOVA global test did suggest there was a significance in
differences between the means. No significant group differ-
ences were found for IFM complex I activity (Figure 6K),
complex III activity (Figure 6L), or complex IV activity
(Figure 6M); however, the global analysis did show that a
significant difference existed for the IFM ATP synthase
activity (Figure 6N).
Discussion
In skeletal muscle, SIRT1 has been established as a regulator
of PGC1α and consequently, mitochondria,21,56 which are im-
portant for generating ATP during muscle repair. SIRT1 is gen-
erally high in type I fibres and promoted by endurance
exercise.48 Because type I oxidative fibres are generally
though to resist aging-related atrophy, SIRT1 has become a
target of interest in studies of sarcopenia with a potential role
in preventing muscle wasting. Support for this idea came
from studies that show overexpression of SIRT1 prevented
type I fibre atrophy under conditions of long-term caloric def-
icit.15 Furthermore, SIRT1 overexpression also improved the
pathophysiology of muscle wasting including Duchenne mus-
cular dystrophy.50 The data in the present study show that
SIRT1 is important for proper muscle function in older mice,
with loss of function most impactful to muscle satellite cells.
This suggests that SIRT1 may have a role in satellite cell reg-
ulated muscle repair. Unexpectedly, both our SIRT1 overex-
pressing model (OE-80) and skeletal muscle-specific SIRT1
knockout model (MKO-80) demonstrated increased resis-
tance to muscle fatigue after recovering from acute CTX-
induced muscle damage. Although knocking out SIRT1 in sat-
ellite cells impairs muscle contraction in aged mice, ablation
of SIRT1 from skeletal muscle promotes satellite cell prolifer-
ation and therefore the muscle’s regenerative capacity, sug-
gesting that the most beneficial or detrimental effects of
SIRT1 may be determined by its site of localization within
muscle cells.
Muscle and satellite cell loss of SIRT1
Interestingly, the MKO and SKO models showed differential
effects for SIRT1 knockout. The MKO mice had a greater resis-
tance to fatigue after repair following CTX injury but a similar
level of regenerative capacity as compared to the older
models. In contrast to the SKO model, the cre protein in
the MKO model is induced by the MCK promoter, so SIRT1
is only expressed in mature skeletal muscle. In contrast, the
SKO model’s cre protein is promoted by PAX7 so that SIRT1
is inactive in only satellite cells, but not in skeletal muscle
when PAX7 is downregulated.
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Satellite cell but not muscle loss of SIRT1 reduces
maximal force production
Muscles from older MKO mice did not have a loss of muscle
force production when compared to age-matched or 20-
week-old and wild-type control mice. This suggests that loss
or gain of SIRT1 does not affect the muscle’s ability to gener-
ate maximal muscle force (presumably by not affecting the
number or general function of the myosin cross bridges). In
contrast, SKO mice that have a satellite cell specific loss of
SIRT1 had lower overall plantarflexion force than young or
older wild type or SIRT1 overexpressor mice, although gas-
trocnemius and soleus muscles were not markedly smaller
in this group. This suggests that loss of SIRT1 in satellite cells
did not change overall cross bridge number in the muscle’s
CSA, but interestingly, it did affect muscle function. While it
is possible that SIRT1 could affect force per cross bridge, we
think a more likely possibility is that the lower force output
in muscles from SKO mice may indicate a neural problem
which resulted in an incomplete activation of muscle in the
old mice. This could potentially occur at the level of the neu-
romuscular junction perhaps as an accelerated aging loss of
dystrophin.57 However, this study was not designed to evalu-
ate the role of SIRT1 in neural regulation of force.
SIRT1 expression may improve but is not necessary
for recovery of muscle function after injury
Muscle repair is dependent upon satellite cell activation and
satellite cell function thought to be depressed with ag-
ing.23,52 In elderly humans, SIRT1 activation by resveratrol
was shown to be associated with increased satellite cell ac-
tivation in response to loading exercise.27 Although the
MKO-80 and OE-80 aged models in our study vary with re-
spect to their levels of SIRT1 expression in skeletal muscle,
both groups showed some improvement in fatigue resis-
tance in response to repeated contractions of muscles in
hindlimbs previously injured by CTX as compared to unin-
jured control muscles. This fatigue resistance was not
reproduced in CTX-injured hindlimbs for the YWT, WT-80,
or SKO-80 models after a 21-day recovery period that was
observed in the other groups. Furthermore, none of the five
animal groups experienced a loss of function during the
fatigue testing in hindlimbs injured by CTX or injected with
the PBS control, indicating that functional recovery of
skeletal muscle is not influenced by loss or gain of SIRT1
abundance in skeletal muscle. The gain of function after in-
jury in both SIRT1 overexpressor and SIRT1 knockout
models suggests a common repair-induced modification in
muscle function may exist as long as some SIRT1 is present
in satellite cells (even if it does not exist in the muscle cells
per se).
SIRT1 loss in muscle increases acute, but not
long-term proliferation of satellite cell
Ryall and colleagues reported that knocking SIRT1 out of sat-
ellite cells caused premature differentiation of satellite
cells,29 and therefore, we expected SIRT1 loss or overexpres-
sion would induce different satellite cell proliferation re-
sponses after CTX injury.
In vitro analysis of cell proliferation within 24 h of culturing
isolated satellite cells showed that a muscle knockout of
SIRT1 had the greatest potential for satellite cell proliferation
among the experimental groups. Of the five experimental
groups, only the MKO model lacked expression of SIRT1 in
skeletal muscle (despite PAX7 not being expressed in skeletal
muscle, western blots showed reduced or ablated bands for
SKO mice, which should only lack SIRT1 in satellite cells).
However, because the SKO muscles showed a comparatively
blunted level of proliferation compared to the MKO model,
muscle loss of SIRT1 while maintaining satellite cell SIRT1 ap-
peared to increase satellite cell proliferation. However, this
potential was not realized in vivo in response to repair follow-
ing CTX injury.
In vivo proliferation was assessed 21 days after acute CTX
injury in muscles of older mice and was reflected by the fre-
quency of BrdU+ nuclei present in muscle sections post-
repair. As 21 days represents a point where recovery from
acute injury should be complete, this experiment reflected
long-term satellite cell proliferation following an acute injury
and not the rate of cell proliferation. After 21 days, the MKO
model no longer had the greatest proliferation capacity but
instead was the only SIRT1-expressor variant that did not dif-
fer significantly in the number of BrdU+ nuclei quantified in
the older, WT-80 group. Both OE-80 and SKO-80 showed sig-
nificantly fewer BrdU+ cells relative to the WT-80 and MKO-
80 models. This indicates that factors outside of the satellite
cells (potentially crosstalk between muscle and satellite cells)
in vivo limited satellite cell proliferation in muscles of old an-
imals, and one of those could be muscle SIRT1.
Mitochondrial function and SIRT1 in muscle
As SIRT1 has a role in regulating oxidative metabolism and
connecting global metabolism to longevity and regeneration,
we also examined mitochondrial subpopulations to identify
potential differences in these subpopulations resulting from
variant SIRT1 expression. Mitochondrial dysfunction may be
a fundamental component that regulates aging responses
along several pathways.27,58 Previous work has suggested
that IFM and SSM subpopulations are affected differently
in cardiac muscle by diabetes.54 Furthermore, SIRT1 is a
regulator of PGC1α which moderates mitochondrial
proliferation.59
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As a reduced mitochondrial membrane potential has been
characterized as an effect of aging and correlates with in-
creased reactive oxygen species (ROS) production,55,60 we
had expected that mitochondrial membrane potential
(ΔΨm) would be improved when SIRT1 was overexpressed
in muscles of older mice, but this was not the case. Interest-
ingly, we saw that muscles from older mice overexpressing
SIRT1 had a significantly lower ΔΨm and ATP synthase activity
in the SSM subpopulation. While we found a significant F ratio
for IFM ΔΨm by one-way ANOVA, there was no significance
difference in mitochondrial function between animal groups
(denoted in our figures by F*), for IFM-ΔΨm and IFM ATP
synthase activity. The IFM results may have been a function
of significant differences in activity that were masked by the
low sample sizes of the experiments. While it is possible that
the decrease in ΔΨm in muscle mitochondria from SIRT1
overexpressor mice may extend to the IFM subpopulation
as well, we cannot verify this in the current study.
Despite loss of SIRT1 function, there was no significant dif-
ferences in muscle mitochondrial characteristics among MKO-
80, SKO-80, and YWT mice aside from significantly increased
size in the older mice (perhaps as a function of decreased mi-
tochondrial fission or increased fusion). Because analysis of
these mitochondria was performed on isolated skeletal mus-
cle and not isolated satellite cells, some differences in mito-
chondrial characteristics may be present during the repair
process in satellite cells that could contribute to a reduced
maximal contraction force in muscles of SKO-80 mice, or
the increase in proliferation of satellite cells seen in MKO-80
mice. However, the similarities between the experimental
models for the majority of the mitochondrial factors closely
reflects the physiological data that showed little change be-
tween muscle fatigability between pretreatment and saline-
injected control groups. The reduced ΔΨm and ATP synthase
activity in SSM from OE-80 mice, coupled with the signifi-
cantly reduced number of proliferating BrdU+ cells detected
after injury, support the idea that mitochondria dysfunction
may impair the recovery of muscle injury in aging.61 The force
and fatigue data collected before and after injury suggest
that alterations in mitochondria characteristics did not impair
muscle function after repair from CTX-induced injury.
One explanation for the increased satellite cell prolifera-
tion seen in MKO-80 mice after injury and the blunted satel-
lite cell response seen in the OE-80model might be related to
the mitochondrial related ROS concentration in the relative
cellular environments. For example, attenuation of muscle re-
generation in satellite cells from old mice was shown to de-
crease when aged satellite cells were paired to young
circulatory environments,23 indicating that repair can be in-
fluenced by the local cellular environment. Several studies
have suggested that excess ROS generated from mitochon-
drial respiration can damage cellular structures and may con-
tribute to cellular aging.62 It is possible, although speculative,
that skeletal muscle containing high levels of SIRT1 may
release more mitochondrial-associated ROS than SIRT1
knockout models during injury and repair and thereby impair
the proliferation capacity in satellite cells during muscle re-
pair. Although our study was not designed to measure ROS
levels, we did see a reduction in SSM-ΔΨm and in ATP syn-
thase activity for the OE-80 model. Reduced NAD+ and SIRT1
activity has been observed in aged tissues, concurrent with
reduced mitochondrial respiratory chain activity and de-
creased expression of proteins that protect against oxidative
damage.63 Conversely, treatment with nicotinamide, the pre-
cursor to the SIRT1 cofactor nicotinamide adenine dinucleo-
tide (NAD+), has been shown to increase mitochondrial
membrane potential and decrease ROS concentration
through pathways utilizing,64 and pathways independent of
SIRT1.65 It is possible that the OE-80 model, which has in-
creased expression of SIRT1 and a decreased SSM-ΔΨm, is
depleting NAD+ more than wild-type or knockout models. If
this was the case, nicotinamide abundance would be de-
creased and ROS abundance would be increased, which in
turn would be expected to reduce satellite cell proliferation
as a result of greater oxidative damage.
As resveratrol-mediated SIRT1 activation was shown to be
protective against ROS-induced mitochondrial-mediated apo-
ptotic signalling in muscle,41 and SIRT1 increases antioxidant
production in muscle,27,32 we had expected that mitochon-
drial function would be improved in muscles that
overexpressed SIRT1 after repair following CTX injury mice.
However, muscles from OE-80 animals had the lowest SSM-
ΔΨm and SSM ATP synthase activity. As SSM lie close to sat-
ellite cells, we would have expected this mitochondrial sub-
population to have the greatest impact on proliferating
satellite cells if mitochondria were important for this process.
Nevertheless, the abundance of BrdU positive satellite cell
nuclei were not different in muscles among OE-80, MKO-80,
or SKO animals after repair from CTX-injury. Thus, the poten-
tial for SIRT1 abundance to alter mitochondria did not appear
to affect the potential for satellite cell-proliferation during re-
pair after CTX injury.
p53 protein abundance is increased in SIRT1
variant models that gained improved muscle
function after recovery from cardiotoxin-induced
injury
Tumour suppressor p53 is a well-characterized downstream
target of SIRT1. While SIRT1 deacetylation usually inhibits
p53 activity, p53 can be upregulated through several path-
ways, especially in response to cellular stress or damage.66 In-
deed, p53 was only found to be significantly increased in the
CTX-injured muscle of the OE-80 and MKO-80 models, but
only when compared to basal levels of p53 in control muscles
that have also recovered from CTX injury. Because one of the
main functions of p53 is to repair DNA in response to injury,
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the presence of p53 in the CTX-injured muscles provides a
plausible explanation as to why our OE-80 and MKO-80
mouse models that have opposite protein abundances of
SIRT1 could paradoxically both benefit from CTX-induced in-
jury. Furthermore, p53 has recently begun to emerge as an
important factor in exercise metabolism, as genetic knock-
outs of p53 reduce IFM and SSM mitochondrial yield, inhibit
mitochondrial respiration, and reduce exercise capacity dur-
ing fatiguing exercises in rodent models.67 Interestingly, al-
though the expression of p53 coincides with improved
fatigue resistance in the SIRT1muscle knockout, the improve-
ment in muscle function after CTX-recovery is markedly
greater in the OE-80 model, indicating high synergy between
the abundances of the SIRT1 and the p53 proteins during
muscle recovery.
Expression of p53 may underlie the attenuation of
MKO-induced satellite cell proliferation
Previous work has established that SIRT1 expression in satel-
lite cells helps to maintain the quiescence of satellite cells
and that eliminating SIRT1 in satellite cells causes premature
proliferation.29 Normal downregulation of SIRT1 in satellite
cells precedes a metabolic shift from fatty acid metabolism
to glycolysis, which is a necessary step for the transition be-
tween quiescence and proliferation. Because the metabolic
profile of stem cells also acts to regulate proliferation and
differentiation,68 it is possible that the increased satellite cell
proliferation seen in the MKO mouse model is due to the
absence of SIRT1 in muscle that disrupts the necessary met-
abolic change required to end satellite cell proliferation. This
possibility is strengthened by evidence showing that there is
an increased abundance of p53 in the CTX-injected hindlimb
muscles of the MKO mouse model and that there is an at-
tenuation of satellite proliferation that was identified by
BrdU+ 21-day post-CTX injury. This is because overload-
induced muscle growth increases nuclear p5369 and ablating
p53 activity reduces myoblast differentiation.70 A likely sce-
nario is that in the absence of SIRT1 in MKO muscle causes
satellite cells to undergo increased proliferation (a reduced
proliferation ‘off-signal’), while the overexpression of SIRT1
would inhibit proliferation, which corresponds to a lower
number of BrdU+ cells in the OE-80 model when compared
to WT-80. Ironically, CTX-induced muscle damage that
should promote satellite cell proliferation to stimulate repair
also increased p53 expression, which would be expected to
inhibit proliferation and promote differentiation in satellite
cells of the repairing muscles in MKO-80 mice and poten-
tially lead to muscle growth/repair. This is consistent with
the observation that cell proliferation was attenuated in iso-
lated satellite cells from MKO-80 mice in vitro after 24 h by
EdU analysis.
The synergistic effects of SIRT1 and p53 that
improve fatigue resistance after injury may also
protect type I fibres from sarcopenic wasting
Although the expression of p53 in the CTX-recovery hindlimbs
of the MKO-80 mice provides a possible explanation as to
why the MKO-80 mice have attenuated satellite cell prolifer-
ation after CTX injury and why injury may induce a protective
effect against fatigue, the inhibitory effect that SIRT1 exerts
on p53 suggests that co-expression in muscle fibres should
ablate the protective effects of p53 on fatigability. To the
contrary, our data show that the OE-80 mice gain a strong
protective effect against fatigue when p53 is upregulated in
hindlimbs following CTX injury and even show signs of im-
proving muscle function following injury through post-
activation potentiation.71,72 One possible explanation is that
the inhibition of p53 by SIRT1 only inhibits p53 activity detri-
mental to oxidative fibres, but not mitochondrial function or
DNA repair activity crucial to preventing metabolic ROS dam-
age. Furthermore, p53 is an established upregulator of
immobilization-induced skeletal muscle atrophy.73 Selective
inhibition of this activity could explain why type I muscle fi-
bres are resistant to sarcopenic wasting while type II fibres
selectively undergo atrophy. It will be interesting to deter-
mine in future studies if co-expression of SIRT1 and p53 selec-
tively inhibit atrophy-related activity but not the DNA repair
functions, thereby ensuring that p53 cannot promote atrophy
in oxidative fibres, where SIRT1 is highly expressed.
Study limitations
The loss of older mice which died at old ages prior to
conducting these studies and removal of mice due to deteri-
orating health conditions at old ages limited the number of
animals that were available to complete the experiments
and therefore reduced the power of the study. The low num-
ber of older animals available for this study prevent us from
obtaining mitochondrial measures in muscles after repair
from CTX. The lower than ideal number of animals may also
have contributed to several experiments which had signifi-
cant differences in their global one-way ANOVA analyses
but failed to detect significant between group differences.
Due to the large effect sizes for some of the values calculated
by the respective Cohen’s d statistics, the likelihood that
some differences were masked by the sample size numbers
is high. Increasing the power of these experiments and
expanding the scope of the mitochondrial aspects of the
study to include ROS production and mitochondrial respira-
tion could potentially elucidate a secondary external role of
SIRT1 in modifying satellite cell viability through oxidative
damage and/or mitochondrial dysfunction.
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Conclusions
The expression of SIRT1 in satellite cells is important for the
functional development of skeletal muscle both initially and
for full muscle regeneration. However, despite its functional
significance in immature skeletal muscle, SIRT1 shows modest
benefit on muscle mass or muscle function when it is
expressed in the older skeletal muscle of C57BL6/j-
background mice after acute injury. Our data suggest that
there is little benefit for the physiological force or fatigue re-
sponses by overexpression of SIRT1 in vivo in the repaired
older skeletal muscle of mice in the absence of any other in-
terventions. However, SIRT1 may synergistically improve the
effect of beneficial proteins like p53 after injury, improving
muscle adaptability and functionality. Ablation of basal SIRT1
expression in satellite cells, however, critically impacts
future/mature muscle function, resulting in lower force pro-
duction. The MCK-driven knockout of SIRT1 in the skeletal
muscle of older mice showed an improved satellite cell de-
pendent muscle regeneration potential, but this regeneration
is possibly attenuated by the expression of p53 after muscle
injury. Future work is needed to identify the synergistic ef-
fects between SIRT1 and p53 in muscle repair. We speculate
that the beneficial effects produced by co-expression of SIRT1
and p53 may also underlie important mechanisms related to
longevity, potentially including the mechanism behind type I
fibre preservation during sarcopenia.
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